search
Back to results

MGuard Stent in ST-elevation Myocardial Infarction (GUARDIAN)

Primary Purpose

ST-elevation Myocardial Infarction, Thrombus, Stents

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
MGuard net protective coronary stent
Bare-metal stent and manual thrombectomy device
Sponsored by
Federico II University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for ST-elevation Myocardial Infarction

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • >/= 18-year-old patients, willing to participate the study, after informed consent signature
  • Female not pregnant or potentially child-bearing
  • > 1 mV ST segment elevation in two or more contiguous leads
  • Acute MI lasting more than 30 minutes and less than 12 hours
  • De novo acute MI
  • Infarct related artery reference vessel diameter >/= 2.5 mm
  • Patient suitable for stenting according to vessel and lesion features

Exclusion Criteria:

  • Dual antiplatelet therapy contraindication
  • Ischemic stroke less than 30 days or previous haemorrhagic stroke
  • WBC count less than 1000 per mm3;
  • Platelet count less than 50.000 per mm3
  • Life expectancy less than 1 year
  • Cardiogenic shock at admission
  • Previous stented infarct related artery
  • Stent thrombosis as the responsible for current STEMI
  • Inability to identify infarct related artery
  • True bifurcation lesion, or lesion near a side branch with a reference vessel diameter >/= 2.5 mm that could be diseased after stenting procedure
  • LBBB
  • Definitive pacing (or ECG abnormalities precluding ST-segment resolution evaluation
  • Participation other study

Sites / Locations

  • Federico II University of Naples

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

MGuard

BMS plus thrombectomy

Arm Description

MGuard net protective stent, investigational device

Bare-metal stent plus manual thrombectomy device

Outcomes

Primary Outcome Measures

Number of patients with Myocardial Perfusional Blush Grade 2-3
Myocardial Perfusional Blush Grade 2-3 at the end of the procedure

Secondary Outcome Measures

Number of MACE
Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure.
Complete ST-segment resolution
Complete (>70%) ST-segment resolution at 60 minutes post-revascularization
Thrombolysis in myocardial infarction antegrade coronary flow
TIMI coronary flow at the end of the procedure
Corrected TIMI Frame count
Corrected TIMI Frame count at the end of the procedure
Infarct related area reduction and left ventricular ejection fraction recovery
Six-month infarct related area reduction and left ventricular ejection fraction recovery as compared with infarct related area and and left ventricular ejection fraction at admission.
Procedural device performance
Device performance evaluated during the procedure in terms of pushability, trackability, crossability and deliverability
Number of MACE
Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure.
Number of MACE
Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure.

Full Information

First Posted
April 8, 2010
Last Updated
March 15, 2022
Sponsor
Federico II University
search

1. Study Identification

Unique Protocol Identification Number
NCT01124942
Brief Title
MGuard Stent in ST-elevation Myocardial Infarction
Acronym
GUARDIAN
Official Title
MGuard vs bAre-metal Stents Plus Manual Thrombectomy in Real World STEMI Patients: a Prospective Multicenter Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
March 1, 2010 (Actual)
Primary Completion Date
March 1, 2011 (Actual)
Study Completion Date
March 1, 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Federico II University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The Investigators will test the hypothesis that MGuard net protective stent, the investigational device, would be superior to conventional revascularization strategy (i.e. bare-metal stenting plus manual thrombectomy), for STEMI patients undergoing urgent percutaneous coronary interventions.
Detailed Description
Embolization of thrombotic debris still represents a complication for ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary interventions (PCI). Distal embolization may decrease coronary and myocardial reperfusion after PCI in STEMI setting. Unfortunately, intracoronary filters present several important limitations limiting their use and their efficacy especially in presence of huge amount of thrombus. In this respect, recent trials investigated whether a default manual thrombectomy strategy before stenting would ameliorate angiographic as well as clinical outcomes for STEMI patients undergoing percutaneous revascularization. Of note, the most of embolization occurs when guidewire, and thrombectomy device cross the thrombus, and after the stent has been implanted as a consequence of plaque prolapse through the stent struts. MGuard net protective stent, the investigational device, is a bare-metal stent covered with a ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, that is anchored to the external surface of the struts. This biocompatible fiber net (string diameter 10-22 μm) has minimal effects on the stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net and isolating the prothrombotic intima components from the blood stream. This protocol will test the hypothesis that MGuard stent would be superior to conventional revascularization strategy (i.e. bare-metal stenting plus manual thrombectomy), for STEMI patients undergoing urgent PCI in terms of angiographic as well as clinical outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ST-elevation Myocardial Infarction, Thrombus, Stents

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
350 (Actual)

8. Arms, Groups, and Interventions

Arm Title
MGuard
Arm Type
Experimental
Arm Description
MGuard net protective stent, investigational device
Arm Title
BMS plus thrombectomy
Arm Type
Active Comparator
Arm Description
Bare-metal stent plus manual thrombectomy device
Intervention Type
Device
Intervention Name(s)
MGuard net protective coronary stent
Other Intervention Name(s)
MGuard net protective stent
Intervention Description
It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 μm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.
Intervention Type
Device
Intervention Name(s)
Bare-metal stent and manual thrombectomy device
Intervention Description
Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent
Primary Outcome Measure Information:
Title
Number of patients with Myocardial Perfusional Blush Grade 2-3
Description
Myocardial Perfusional Blush Grade 2-3 at the end of the procedure
Time Frame
30 minutes after revascularization
Secondary Outcome Measure Information:
Title
Number of MACE
Description
Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure.
Time Frame
1 month
Title
Complete ST-segment resolution
Description
Complete (>70%) ST-segment resolution at 60 minutes post-revascularization
Time Frame
60 minutes after revascularization
Title
Thrombolysis in myocardial infarction antegrade coronary flow
Description
TIMI coronary flow at the end of the procedure
Time Frame
30 minutes after revascularization
Title
Corrected TIMI Frame count
Description
Corrected TIMI Frame count at the end of the procedure
Time Frame
30 minutes after revascularization
Title
Infarct related area reduction and left ventricular ejection fraction recovery
Description
Six-month infarct related area reduction and left ventricular ejection fraction recovery as compared with infarct related area and and left ventricular ejection fraction at admission.
Time Frame
6 months
Title
Procedural device performance
Description
Device performance evaluated during the procedure in terms of pushability, trackability, crossability and deliverability
Time Frame
60 minutes after revascularizationl
Title
Number of MACE
Description
Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure.
Time Frame
6 months
Title
Number of MACE
Description
Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure.
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: >/= 18-year-old patients, willing to participate the study, after informed consent signature Female not pregnant or potentially child-bearing > 1 mV ST segment elevation in two or more contiguous leads Acute MI lasting more than 30 minutes and less than 12 hours De novo acute MI Infarct related artery reference vessel diameter >/= 2.5 mm Patient suitable for stenting according to vessel and lesion features Exclusion Criteria: Dual antiplatelet therapy contraindication Ischemic stroke less than 30 days or previous haemorrhagic stroke WBC count less than 1000 per mm3; Platelet count less than 50.000 per mm3 Life expectancy less than 1 year Cardiogenic shock at admission Previous stented infarct related artery Stent thrombosis as the responsible for current STEMI Inability to identify infarct related artery True bifurcation lesion, or lesion near a side branch with a reference vessel diameter >/= 2.5 mm that could be diseased after stenting procedure LBBB Definitive pacing (or ECG abnormalities precluding ST-segment resolution evaluation Participation other study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Federico Piscione, Associate Professor
Organizational Affiliation
Federico II University of Naples
Official's Role
Study Chair
Facility Information:
Facility Name
Federico II University of Naples
City
Naples
ZIP/Postal Code
80131
Country
Italy

12. IPD Sharing Statement

Citations:
PubMed Identifier
19937780
Citation
Piscione F, Danzi GB, Cassese S, Esposito G, Cirillo P, Galasso G, Rapacciuolo A, Leosco D, Briguori C, Varbella F, Tuccillo B, Chiariello M. Multicentre experience with MGuard net protective stent in ST-elevation myocardial infarction: safety, feasibility, and impact on myocardial reperfusion. Catheter Cardiovasc Interv. 2010 Apr 1;75(5):715-21. doi: 10.1002/ccd.22292.
Results Reference
background
PubMed Identifier
20093945
Citation
Rapacciuolo A, D'andrea C, Maresca G, di Pietro E, Piscione F, Chiariello M. Multiple MGuard stent implantation to treat massive right coronary artery dissection during primary coronary angioplasty. J Cardiovasc Med (Hagerstown). 2011 May;12(5):356-60. doi: 10.2459/JCM.0b013e328334092d.
Results Reference
background

Learn more about this trial

MGuard Stent in ST-elevation Myocardial Infarction

We'll reach out to this number within 24 hrs